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Preexposure prophylaxis (PrEP) is a biomedical intervention to prevent the spread of HIV. 
Underprescribing PrEP could increase the probability of HIV exposure among serodivergent 
couples/partners and people who do not practice safer sex. Previous research on PrEP did not 
assess the association between awareness of PrEP, years of experience of the providers, 
provider types, and the frequency of PrEP among physicians. The purpose of this study is to 
test the hypothesis that awareness of PrEP, years of experience, and provider types might be 
predictors of the frequency of PrEP among physicians. Precaution adoption process model 
and cross-sectional design were applied to survey 100 physicians. Kendall's b correlation test 
and Fisher’s exact test showed that awareness was the primary barrier to prescribing PrEP 
at the providers’ level. Higher awareness of PrEP and years of experience were associated 
with the frequency of PrEP prescription. However, there was an insignificant difference 
between provider types and the frequency of PrEP prescription. The findings support the 
notion that independent from their years of experience and specialty, the more physicians 
know about PrEP, the more they prescribe it. The results and recommendations contribute to 
positive social change by providing information to develop a comprehensive PrEP education 
curriculum for care providers. Our findings indicate that physicians need education and 
training to fully understand the potential for PrEP to reduce HIV transmission.   
Keywords: preexposure prophylaxis (PrEP), HIV, precaution adoption process model (PAPM), 
serodivergent relationship, Truvada 
 
  
 Logo et al., 2017 
 




HIV is still among the top three public health concerns in the United States (Centers for Disease 
Control and Prevention [CDC], 2013). Despite the large amounts of money and steady effort put into 
research and prevention programs, the United Stated registers 50,000 new HIV cases yearly (CDC, 
2013). HIV preexposure prophylaxis (PrEP) is a revolutionary, novel biomedical intervention in the 
last 6 years. PrEP regimen1 is recommended to HIV-negative people who might be at higher risk for 
the HIV infection like serodivergent couples/partners2 (AIDS.gov, 2014). For different reasons, it 
makes sense to use PrEP to prevent HIV (World Health Organization [WHO], 2013). For example, 
antiretroviral therapy has 96% efficacy against HIV transmission to the uninfected people who are 
at higher risk. These individuals include serodiscordant partners, men who have sex with men, 
needle-sharing drug users, and sex workers (CDC, 2013; Rosenthal et al., 2013). 
However, Cairns (2013) reported that physicians do not prescribe PrEP very often in some 
geographic areas because they lack information about it. Even though some health insurance 
companies cover HIV PrEP (Horberg, 2012; Liu et al., 2014), physicians are reluctant to prescribe it 
(Krakower & Mayer, 2013), but it is unclear why. In this study, we examined the role of HIV PrEP 
awareness, providers’ years of service, and provider types as predictors of the frequency of PrEP 
prescription among care providers. A better understanding of the knowledge, behavior, and attitudes 
of physicians regarding the PrEP will better indicate where additional education may be needed.   
                                                          
1 Understanding the PrEP regimen: PrEP is an HIV prevention regimen for HIV-free persons prone to ongoing 
substantial HIV exposure (Aids.gov, 2014). It consists of one pill of Truvada daily as a preventive measure to 
reduce HIV transmission risks (AIDSinfo, 2008). Truvada is made with 200 mg of Emtricitabine and 300 mg of 
tenofovir disoproxil fumarate. As an HIV nucleoside reverse transcriptase inhibitor drug, Truvada stops HIV 
from making copies. Its dosage for PrEP requires in a single pill (Choopanya et al., 2013). It can be (a) used with 
other antiretroviral drugs to treat HIV- positive patients and (b) used alone to prevent HIV infection in HIV-
negative populations. When taken consistently, it has decreased the risk of HIV transmission among HIV-
negative populations (Choopanya et al., 2013). Truvada is a component of PrEP that is a routine procedure. 
PreP regimen has four implementation phases. The first consists of assessing significant risk for HIV infection. 
The second is about establishing PrEP candidates’ eligibility clinically (i.e., documented HIV-negative status, 
documented hepatitis B virus infection/immunization status, and checking for (a) no contraindicated 
medication, (b) no signs of severe HIV infection, and (c) healthy liver and good functioning kidneys). The third 
consists of prescribing Truvada (a steady oral dose of Truvada on the daily basis). The fourth is a follow-up. The 
follow-up services include every 3 months or 6 months for HIV and STI tests, counseling for medication 
adherence, renal function assessment, and pregnancy test for females, clean needles/syringes exchange, and 
substance abuse treatment services. The CDC recommended PrEP in addition to the following: Consistent and 
correct use of condoms,  
• Getting tested periodically for HIV and sexually transmissible diseases,  
• Adopting less risky sexual behaviors, and  
• Using sterilized drug injection equipment or participating in a drug treatment program (Aids.gov, 
2014).  
2 Serodivergent, also called serodiscordant, is associated with partners/couples with opposite HIV status (HIV 
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The Frequency and Challenges of PrEP Prescription 
Providers do not prescribe PrEP to their clients very often in the United States. Krakower and 
Mayer (2013) reported that only 4% of participants had prescribed PrEP. Prescribing PrEP is 
challenging to some care providers. 
According to Castillo (2013), the illiteracy about PrEP can lead to its underprescription. Studies 
focused on PrEP implementation challenges at the clients’ level (Mansergh, Koblin, & Sullivan, 
2012) and barriers to free access to PrEP services (Puro, Palummieri, De Carli, Piselli, & Ippolito, 
2013).  
PrEP Education, Literacy Improvement Needs, and PrEP Guideline 
Education is the key strategy to enhance PrEP literacy. There was a significant relationship between 
awareness of PrEP and the clients’ readiness to use PrEP (Young, Li, & McDaid, 2013). The higher 
HIV infection incidence rate in the United States requires multilevel prevention approaches 
including PrEP education enhancement within care providers (Krakower & Mayer, 2012). 
Researchers at the University of California, Los Angeles showed that the 2014 PrEP guideline might 
overlook or underassess individuals who should be on PrEP (University of California–Los Angeles 
Health Sciences, 2017). It is necessary to develop a research-driven HIV-risk assessment tool to fill 
the gap.  
Need for Further Studies on PrEP: Workers and practitioners at the United 
Nations  
International Children's Emergency Fund, United Nations Program on HIV/AIDS, WHO, and CDC 
agreed that the time had come to promote universal access to prevention and treatment services 
(WHO, 2013). Detailed HIV PrEP guidelines need to be developed to improve physicians’ readiness 
to provide PrEP and behavioral interventions to people at risk for HIV infection (Puro et al., 2013). 
That said, it is apparent that multisector studies of PrEP could provide insights to improve PrEP 
implementation, the gaps in PrEP prescription guideline, and the barriers to prescribe PrEP at the 
physicians level. Our research questions were as follows:  
Research Question 1: What is the association between HIV PrEP awareness and the 
frequency of PrEP prescription among primary association between the number of years of 
service as a primary care provider or HIV specialist and the frequency of PrEP prescription 
among primary care providers and HIV specialists in the Quad Cities area?  
Research Question 2: What is the association between the number of years of service as a 
primary care provider or HIV specialist and the frequency of PrEP prescription among 
primary care providers and HIV specialists in the Quad Cities area?  
Research Question 3: What is the difference between provider types and the frequency of 
PrEP prescription among primary care providers and HIV specialists in the Quad Cities 
area?  
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The focus of this study was to explore HIV/AIDS health-protective behaviors by determining how 
primary care providers and HIV specialists make decisions to prescribe PrEP and how they translate 
their decisions into actions. For this reason, it was appropriate to adopt the precaution adoption 
process model (PAPM) as the theoretical framework to guide this study. We used the adapted visual 
representation (Figure 1) to explain the linkage between PAPM constructs and this study. Developed 
by Janis and Mann, PAPM defines the process in individuals’ decisions making and the conversion of 
the decision into action in seven stages (Glanz, Rimer, & Viswanath, 2008). Stage 1 is the 
unawareness of the health issue phase. In Stage 2, people learn about the problem for the first time 
but are not concerned about it. Stage 3, the decision-making phase, elucidates how individuals have 
concerns about health issues and start thinking about the appropriate responses. At this point, 
people can decide to stay at this stage or resolve to do nothing. This category of people falls under 
Stage 4, “halting” PAPM. The third possibility is to move to Stage 5 through precaution adoption. 
Stage 6, behavior initiation phase, allows people to act. Finally, Stage 7 is when people maintain 
their new behavior over time (Glanz, et al., 2008). PAPM allows inquirers to identify the stages that 
people go through when they start “health-protective behaviors” (Glanz, et al., 2008). It also provides 
indicators that help researchers to determine the factors favoring behavior change from one stage to 
another (e.g., from awareness to action). The model allowed us to identify barriers to PrEP provision 
at each stage.  
We also applied Gollwitzer and Sheeran’s (2006) implementation intentions concept to this study to 
examine how PrEP service implementation intentions can enhance the primary care providers and 
HIV specialists’ willingness to prescribe it. The implementation intentions are a goal-directed 
behavior where people perform Behavior B if they met a Condition C (Gollwitzer & Sheeran, 2006). 
The concept is effective in enhancing past behavior that leads to the prediction of new behavior 
(Orbeil, Hodgldns, & Sheeran, 1997). We assumed that the concept will help primary care providers 
and HIV specialists to meet their PrEP prescription goals. The connection between the study 
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Table 1. Linkage Between Precaution Adoption Process Model (PAPM) Constructs and Study 





Awareness Years of Service 
Difference in 
Provider Type 
Stage 1: Unaware Never heard of 
PrEP 
As an indicator As an indicator 
Stage 2: Unengaged Never thought about 
prescribing 
PrEP 
As an indicator As an indicator 
Stage 3: Undecided  Undecided about 
prescribing 
PrEP 
As an indicator As an indicator 
 
 
Stage 4: Do not want 
to act  
Do not want to 
prescribe PrEP 
As an indicator As an indicator 
Stage 5: Decided to 
act  
Plan to prescribe 
PrEP 
As an indicator As an indicator 
Stage 6: Acting  Prescribing 
PrEP 





As an indicator As an indicator 
Note. The outcome variable is the frequency of PrEP prescription. 
Family practitioners, pediatricians, internists, obstetricians/gynecologists, and infectious 
disease/HIV specialists in the great Quad Cities area, up to a 70-mi radius from the city of Rock 
Island, Illinois, participated in the study. The cities include Davenport, Bettendorf, Clinton, De Witt, 
Wilton, Le Claire, Muscatine, Blue Grass, Eldridge, Orion, Durant, and Iowa City in Iowa and Rock 
Island, Milan, Silvis, East Moline, Moline, Alpha, Cambridge, Fulton, Cordova, Colona, Aledo, Coal 
Valley, and Peoria in Illinois. We sought the permission to conduct this study from the Walden 
University’s Institutional Review Board.  
Our recruitment effort consisted of using internet research tools to search for an updated list of 
primary care providers and HIV specialists practicing in the Quad Cities for May 15, 2015. We 
randomly selected 300 physicians among the 1,139 total physicians in the Quad Cities area.  
We calculated a proportion of 26% (i.e., 300 divided by 1,139 times 100). We applied the 26% 
proportion to the total number of all Physicians in each of the five specialties in the area to 
determine the exact number of physicians to whom we should send the survey per specialty. Our 
final sample consisted of 97 family practitioners (26% of 373), 44 pediatricians (26% of 170), 80 
internists (26% of 308), 41 obstetricians/gynecologists (26% of 158), and 38 infectious disease/HIV 
specialists (26% of 147) to whom we mailed the survey. We distributed the participants evenly across 
sex (150 females and 150 males) and across geographic location (i.e., 150 participants from Illinois 
and 150 from Iowa).  
Our analytic sample was n = 100 respondents (33.3% response rate). We used SPSS and G*power 
analysis tools for the statistics tests. We designed our own survey instrument based on the modified 
Glanz et al. (2008) PAPM stage clarification algorithm (Table 2). Therefore, we pilot tested the 
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instrument to ensure its fitness for the actual study. The pilot testing demonstrated appropriateness 
of the instrument.  
Table 2. Modified Precaution Adoption Process Model (PAPM) Stage Algorithm to Assess 
Preexposure Prophylaxis (PrEP) Awareness  
Questions and Answers 
Corresponding  
PAPM Stage 
1. Have you ever heard about HIV PrEP?  Stage 1 
No   
Yes (go to Question 3)   
2. Have you ever prescribed PrEP to a client?  Stage 6 
Yes   
No (go to Question 3)   
3. Which of the statements below describes better your opinions 
about prescribing PrEP?    
 
I have never thought about prescribing PrEP to clients.  Stage 2 
I am undecided about prescribing PrEP to clients.  Stage 3 
I am resolved to not prescribe PrEP to clients.  Stage 4 
I am resolved to prescribe PrEP to clients.  Stage 5 
Note. Adapted with permission from “Precaution Adoption Process Model: Stage Classification Algorithm,” by K. 
Glanz, B. K. Rimer, & K. Viswanath, Health Behavior and Health Education: Theory, Research, and Practice 
(4th Ed.), p. 136. Copyright 2008 by John Wiley & Sons, Inc. 
Primary quantitative, categorical data including nominal and ordinal data were collected through 
the self-administered paper-based survey between October 24, 2015, and January 24, 2016. The 
United States’ postal mailing system and in-person survey distribution strategy were used to 
distribute the questionnaires. A questionnaire cover letter and a stamped return envelope were 
included in the mailing. The study had one ordinal outcome (i.e., the frequency of HIV PrEP 
prescription) and two nominal independent variables (i.e., HIV PrEP awareness and the difference in 
provider’s type), and one ordinal independent variable (i.e., the number of year of service). We used 
IBM SPSS Statistics 21 for all statistical analysis. 
Results  
Descriptive Statistics  
There were N = 100 valid responses and zero missing data. We evaluated the zip code of respondents 
to determine their geographic location (i.e., Illinois versus Iowa). The majority of participants were 
male and 45 to 54 years old. One quarter of them had 11–15 years of experience as a physician. The 
majority of respondents had very little awareness of PrEP. About 90% of respondents had never 
prescribed PrEP or thought about prescribing PrEP to their clients either. Few participants declared 
that they know much about PrEP and its guidelines/protocol to prescribe or propose its services. For 
example, 87% of the respondents had low awareness about PrEP. Only 10% of respondents had 
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Table 3. Sample Demographics (N = 100) 
Variables Frequency Percent 
 Sex of respondent   
 Male 53 53% 
 Female 47 47% 
 Age range of respondent   
 25–34 13 13% 
 35–44 21 21% 
 45–54 31 31% 
 55–64 28 28% 
 65–74 7 7% 
 Location of respondent   
 Illinois 48 48% 
 Iowa 52 52% 
 Year of experience of respondent    
 0–5 years 14 14% 
 6–10 years 16 16% 
11–15 years 20 20% 
16–20 years 14 14% 
21–25 years 18 18% 
26+ years 18 18% 
Specialty   
Family practitioners 30 30% 
Infectious disease/HIV specialists 11 11% 
Internists 17 17% 
Obstetricians/gynecologists 19 19% 
Pediatricians 17 17% 
 
Main Analyses  
Two-sided Fisher's exact test revealed that the differences in the frequency of PrEP prescription 
across physicians’ specialties were not statistically significant. There was a statistically significant 
association between years of experience and the frequency of PrEP prescription (p = .002, two-sided 
Fisher's exact test). Pearson chi-square test showed a significant association between awareness of 
PrEP and the frequency of PrEP prescription (p = .017). The association between years of experience 
and the frequency of PrEP prescription was statistically significant too, confirming the result of 
Fisher’s exact test performed earlier. Gender difference and geographic location covariates were not 
associated with the frequency of PrEP prescription.  
Kendall's τb correlation test showed a moderate, negative correlation between awareness of PrEP 
and the frequency of PrEP prescription that was statistically significant (τb = –.367, p < .001). The 
frequency of PrEP prescription decreases. Kendall's τb correlation test also showed a weak negative 
correlation between years of service and the frequency of PrEP prescription that was statistically 
significant (τb = –.228, p = .010). The frequency of PrEP prescription decreases when the number of 
years of service as a primary care provider decreases. Fisher’s exact test of Research Question 3 
showed no significant difference at the .05 significance level (p = .130).  
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The results of the study provided information on the physicians’ attitudes corresponding to each 
stage of the constructs of PAPM. For example, some participants are unaware of the issue. Some are 
aware but are unengaged. Others are undecided about taking action or decided not to act. Few of 
them have decided that they want to prescribe PrEP and will continue prescribing PrEP.  
Based on our understanding of PrEP and PAPM, there are several interpretations of our findings.  
Stage 1: Unaware 
About one fifth of the physicians had never heard of PrEP. Therefore, they will never prescribe 
PrEP. This finding indicated the need for basic information (education) on PrEP for care providers. 
They will make best judgments about prescribing PrEP if they were PrEP literacy competent. They 
could then move to the next PAPM stages (i.e., unengaged, undecided, decided to act, or decided not 
to act).  
Stage 2: Unengaged 
About 70% of the participants learned very little or a little about PrEP. However, they were not yet 
engaged with the issue of under-prescribing PrEP. This finding is a call for formal education/training 
for the majority of physicians. It would allow HIV/AIDS prevention program developer to use 
training methods that make the PrEP issue and the need for action personally important to those 
unengaged physicians.  
Stage 3: Undecided 
About one quarter of the surveyed physicians were undecided about prescribing PrEP, meaning that 
they were engaged with the issue and looking for how to proceed. Because they did not yet form an 
opinion about prescribing PrEP, they would be less resilient to persuasion (DiClemente, Crosby, & 
Kegler, 2002). The relevance of this finding is to remind potential PrEP providers about improving 
their PrEP literacy by exploring available PrEP provision protocol and guideline. For example, cross-
training among physicians within the same agency and coaching by PrEP experts through technical 
training is necessary for undecided physicians.  
Stage 4: Decided Not to Act 
Less than 5% of the surveyed physicians said that they do not want to prescribe PrEP. We assumed 
these people were aware of PrEP but have unexpressed reasons that challenge their decision to 
prescribe it. DiClemente et al. (2002) stated that those individuals might be difficult to persuade, 
and they ceased the PAPM process. On the other hand, some may hold off on deciding and stay 
undecided (Stage 3). This finding inspired the question about a suitable approach to engaging 
informed people who are refractory with prescribing PrEP. Proactively identifying these barriers to 
PrEP education programs would help health educators to use an alternative model to overcome 
them.  
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Stage 5: Decided to Act 
About 15% of the participants said that they plan to prescribe PrEP. One assumed that these 
individuals were conscious of the risks for not prescribing PrEP and the outcomes. Therefore, they 
decided to prescribe it. With this finding, researchers provided an empirical data as baseline 
information to measure the percentage of physicians who are ready to prescribe PrEP in the Quad 
Cities area as of October 2016.  
Stage 6: Acting 
Ten percent of the surveyed physicians are prescribing PrEP. Researchers also assumed that PrEP 
providers have some intrinsic and extrinsic motivations that were not examined in this study. 
Refreshment PrEP training is needed to empower that target population to continue prescribing 
PrEP.  
Stage 7: Maintenance 
The study did not provide relevant data to quantify the number of physicians who have maintained 
their prescribing of PrEP over time. Further investigation of this aspect of PAPM is desirable.  
Providers’ readiness to prescribe PrEP and patients’ willingness to adopt it are the sine-qua-non 
conditions to promote PrEP regimen in the Quad Cities. However, researchers did not examine 
patients’ attitudes toward, or need for, PrEP services in this study because the issue regarding 
prescribing PrEP in the Quad Cities was investigated at providers’ level only.  
The findings disconfirmed the assumption that the frequency of PrEP prescription is different as far 
as the physicians’ specialty. Furthermore, the results did not support the hypothesis that there is a 
difference in provider types and the frequency of PrEP prescription among primary care providers 
and HIV specialists. Also, while Horberg and Raymond (2013) found that the high cost of PrEP could 
dissuade its prescribers and users, this study revealed that excessive cost and coverage of PrEP 
issues were not the primary barriers to prescribing it. Finally, the findings were opposite those of 
Puro et al. (2013), who demonstrated that only HIV/AIDS specialists had a privilege to prescribe 
PrEP. In fact, this study showed that even non-HIV/AIDS specialists (i.e., family practitioners, 
internists, obstetricians/gynecologists, and pediatricians) had prescribed PrEP.  
The findings both confirmed and disconfirmed many results from the literature review on the 
concepts and key variables. For example, this study revealed the need for PrEP education and 
literacy improvement for physicians. Likewise, Krakower and Mayer (2012) showed that PrEP 
education enhancement within care providers is desirable to limit the higher HIV infection incidence 
rate in the United States.  
Limitations  
Response bias could arise from this study because of the self-reported survey. Although we strived to 
include more primary care physicians from different specialties, the physicians surveyed in this 
study did not represent a sample of all care providers who can prescribe PrEP in the United States. 
We aligned the questions strictly to the study’s theoretical framework context to limit the response 
biases. Therefore, we are limited in the generalizability of the study. Future research could improve 
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generalizability with a large sample size, including other medical specialties such as physician 
assistants and certified nurse practitioners.  
Recommendations  
To promote PrEP implementation and education, further implementation research is needed to 
understand and improve PrEP delivery at local and state levels. The approach is crucial to the better 
identification of, and response to, the gaps in PrEP prescription. Other calls for action include the 
necessity to 
• develop a comprehensive PrEP education curriculum that aligns to the PAPM for care 
providers nationwide;  
• include PrEP topics into the continued education online training modules for all physicians, 
physician assistants, and nurse practitioners;  
• develop policies that support integrated PrEP implementation strategies (the strategies 
could consist of using HIV test to inform on PrEP, adding PrEP to risk assessment 
counseling process, integrating PrEP referrals into partner services, sexually transmitted 
disease clinics, and social network strategies);  
• educate and train providers such as case managers, outreach staff, and testing counselors 
about PrEP guideline, PrEP protocols, its advantages and limits; and  
• take PrEP information beyond care providers to the community at large through community 
forums, community outreaches, seminaries, peer education, and webinars.  
 
Positive Social Change Impact  
By empowering care providers to prescribe PrEP more often to vulnerable populations including 
persons in a serodiscordant relationship and others, the findings have potentials to bring positive 
changes to individuals and their families. The direct impacts include peace of mind and elimination 
of fear of the HIV infection. PrEP brings new dynamics (i.e., confidence, psychological supports, love, 
harmony, sexual freedom, etc.) in the family of serodiscordant individuals and also prevents new 
HIV infections. Providing PrEP to the professional sex workers and individuals with multiple sex 
partners will reduce HIV infection in the community. At the organizational level, it does contribute 
knowledge to the field of public health education. Further, this study presents PAPM as a potential 
evidence-based theoretical framework for future PrEP interventions.  
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